these changes consist in the transient suppression of phagocytosis , including a decrease in the activity of intraleukocytic bactericidal systems ( myeloperoxidase and cation protein ) , a decrease in the activity of the complement and the bactericidal activity of the blood serum , which should be taken into account when using this immune preparation for therapy .
C0009498
complement
C0229671
serum